Vir Biotechnology (NASDAQ:VIR) EVP Sells $26,717.70 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Vanina de Verneuil sold 2,407 shares of the company’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $11.10, for a total transaction of $26,717.70. Following the transaction, the executive vice president directly owned 110,193 shares in the company, valued at approximately $1,223,142.30. This trade represents a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Verneuil Vanina De also recently made the following trade(s):

• On Monday, November 2nd, Vanina de Verneuil sold 1,343 shares of Vir Biotechnology stock. The shares were sold at an average price of $11.33, for a total value of $15,216.19.

Vir Biotechnology Stock Up 10.8%

Shares of NASDAQ VIR opened at $12.21 on Friday. The company’s fifty day simple moving average is $11.03 and its 200 day simple moving average is $9.61. The firm has a market cap of $2.07 billion, a PE ratio of -9.69 and a beta of 1.70. Vir Biotechnology, Inc. has a 12-month low of $4.82 and a 12-month high of $12.45.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.18. The firm had revenue of ($0.19) million for the quarter, compared to analysts’ expectations of $0.98 million. During the same quarter in the prior year, the business posted ($1.17) EPS. The business’s quarterly revenue was down 178.3% on a year-over-year basis. On average, equities analysts predict that Vir Biotechnology, Inc. will post -1.84 earnings per share for the current year.

Wall Street Analyst Weigh In

VIR has been the subject of several recent analyst reports. Zacks Research raised shares of Vir Biotechnology from a “strong sell” rating to a “hold” rating in a report on Wednesday. Needham & Company LLC raised their price objective on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday. Wall Street Zen upgraded shares of Vir Biotechnology from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Friday, October 2nd. Finally, Morgan Stanley set a $25.00 price target on shares of Vir Biotechnology in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Vir Biotechnology currently has an average rating of “Moderate Buy” and a consensus target price of $22.14.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Fiduciary Financial Advisors bought a new position in Vir Biotechnology during the 2nd quarter worth approximately $29,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Vir Biotechnology during the third quarter worth about $97,000. Caxton Associates LLP bought a new position in Vir Biotechnology during the 1st quarter worth approximately $112,000. Amundi boosted its stake in Vir Biotechnology by 52.8% in the 1st quarter. Amundi now owns 15,315 shares of the company’s stock worth $137,000 after purchasing an additional 5,294 shares during the period. Finally, Royal Bank of Canada boosted its position in shares of Vir Biotechnology by 223.1% during the 1st quarter. Royal Bank of Canada now owns 15,355 shares of the company’s stock valued at $138,000 after acquiring an additional 10,603 shares in the last quarter. 65.32% of the stock is owned by institutional investors.

Trending Headlines about Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Analyst sentiment improved: Needham raised its price target to $20 from $18 and maintained a Buy rating. Zacks Research also upgraded VIR from Strong Sell to Hold, reducing a bearish signal. Needham rating Zacks rating
• Positive Sentiment: Key clinical catalyst ahead: Vir plans to present topline Phase 3 ECLIPSE 1 results for elebsiran and tobevibart in chronic hepatitis delta at AASLD’s 2026 liver meeting. Positive data could be a meaningful catalyst, though the outcome is uncertain. AASLD data presentation
• Positive Sentiment: Cash runway extends into the second half of 2028, giving the company additional time to advance its pipeline and reach development milestones. Cash runway update
• Neutral Sentiment: Q3 loss beat expectations: Vir reported a loss of $0.57 per share, narrower than analysts’ expected loss of about $0.75–$0.80 and the $1.17 loss a year earlier. Q3 results
• Neutral Sentiment: An executive sold a small number of shares under a pre-arranged plan to cover tax withholding on vested equity awards; the stated purpose makes this less indicative of a change in outlook. SEC filing
• Negative Sentiment: Revenue missed sharply: Q3 revenue was negative $0.19 million versus analysts’ estimate of $0.98 million, and was down 178.3% year over year, tempering the earnings beat. Revenue results

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.